Moderna COVID-19 Vaccine
The FDA has authorized updated, bivalent mRNA COVID-19 vaccines for all doses in individuals aged 6 months and older. This update specifically pertains to the Moderna COVID-19 Vaccine, Bivalent formulation.
This update affects the manufacturer (Moderna), healthcare providers administering the vaccine, and regulatory/clinical operations teams responsible for overseeing vaccine deployment and compliance for populations aged 6 months and older.
The expansion to all doses for individuals as young as 6 months suggests a shift toward the bivalent formulation as the primary standard for mRNA vaccination. Regulatory professionals should note that this authorization likely supersedes previous monovalent dosing schedules for these age groups, requiring updates to clinical protocols and compliance monitoring.
Regulatory teams should ensure that all internal product documentation and labeling reflect the current authorization status for the bivalent formulation across the pediatric and adult spectrum. Quality and clinical teams should verify that administration protocols align with the expanded age indications (6 months and older) for all doses.
Information about Moderna COVID-19 Vaccine, Bivalent. Updated, bivalent mRNA COVID-19 vaccines are now FDA-authorized for all doses for individuals ages 6 months and older.
Open in openFDA / FDA.gov